INNATE PHARMA SA (IPHA): Price and Financial Metrics
GET POWR RATINGS... FREE!
IPHA Stock Summary
- IPHA's went public 1.94 years ago, making it older than merely 3.25% of listed US stocks we're tracking.
- In terms of twelve month growth in earnings before interest and taxes, Innate Pharma SA is reporting a growth rate of 402.37%; that's higher than 94.11% of US stocks.
- As for revenue growth, note that IPHA's revenue has grown -37.7% over the past 12 months; that beats the revenue growth of merely 6.91% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Innate Pharma SA are AUMN, FF, SNCR, LMNL, and RBBN.
- IPHA's SEC filings can be seen here. And to visit Innate Pharma SA's official web site, go to www.innate-pharma.com.
IPHA Stock Price Chart Interactive Chart >
IPHA Price/Volume Stats
|Current price||$6.70||52-week high||$11.95|
|Prev. close||$7.00||52-week low||$3.02|
|Day high||$7.13||Avg. volume||843,577|
|50-day MA||$4.30||Dividend yield||N/A|
|200-day MA||$4.26||Market Cap||530.40M|
INNATE PHARMA SA (IPHA) Company Bio
Innate Pharma SA is a biopharmaceutical company, which focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. Its products include immunotherapy drugs and monoclonal antibodies. The Immunotherapy drugs are designated for cancer and inflammatory diseases. The Monoclonal antibodies targets receptors and pathways controlling the activation of innate immunity cells.
Most Popular Stories View All
IPHA Latest News Stream
|Loading, please wait...|
IPHA Latest Social Stream
View Full IPHA Social Stream
Latest IPHA News From Around the Web
Below are the latest news stories about Innate Pharma SA that investors may wish to consider to help them evaluate IPHA as an investment opportunity.
Marseille, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well as its voting rights as at September 1, 2021: Total number of shares outstanding:79,294,402 ordinary shares 6,784 Preferre
Good morning, trader!
Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares jumped 135.4% to settle at $5.32 on Friday. The stock possibly traded higher following favorable data results by AstraZeneca for patients with unresectable, stage 3 non-small cell lung cancer. Helbiz, Inc. (NASDAQ: HLBZ) shares surged 96.6% to close at $17.69 on Friday after the company announced its media unit has entered into an agreement with FOX Networks to broadcast the Italian Serie B championship across the USA and the Caribbean.
There's only one day of trading left so let's start it off right with a look at the biggest pre-market stock movers for Friday.
Innate Pharma SA (NASDAQ: IPHA ) stock is trading at a 52-week high as its partner AstraZeneca Plc (NASDAQ: AZN ) presented results from the COAST Phase 2 trial during the European Society for Medical Oncology ( ESMO21 ) Congress 2021. The trial included patients with unresectable, Stage 3 non-small cell lung cancer (NSCLC) who had not progressed after concurrent chemoradiation therapy (CRT). After a median follow-up of 11.5 months, Imfinzi (durvalumab) plus oleclumab reduced the risk of disease progression or death by 56% (hazard ratio [HR] = 0.44), Imfinzi plus monalizumab Full story available on Benzinga.com
IPHA Price Returns